Tigecycline: A review of a new glycylcycline antibiotic
- 1 January 2005
- journal article
- review article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 16 (4) , 207-212
- https://doi.org/10.1080/09546630510011810
Abstract
Tigecycline derived from minocycline. It is part of a new class of antibiotics called glycylcyclines. Tigecycline is given intravenously and has activity against a variety of gram-positive and gram-negative bacterial pathogens, many of which are resistant to existing antibiotics. Tigecycline successfully completed phase III trials in which it was at least equal to intravenous vancomycin and aztreonam to treat complicated skin and skin structure infections (cSSSI), and to intravenous imipenem and cilastatin to treat complicated intra-abdominal infections (cIAI). Tigecycline side effects are primarily digestive upset. It should be a valuable addition to the armamentarium to treat even the most resistant pathogens.Keywords
This publication has 34 references indexed in Scilit:
- AcrAB Efflux Pump Plays a Role in Decreased Susceptibility to Tigecycline in Morganella morganiiAntimicrobial Agents and Chemotherapy, 2005
- Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- In vitro activities of tigecycline against clinical isolates from Shanghai, ChinaDiagnostic Microbiology and Infectious Disease, 2004
- Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecyclineDiagnostic Microbiology and Infectious Disease, 2004
- In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infectionsDiagnostic Microbiology and Infectious Disease, 2004
- In Vitro Activities of Tigecycline against the Bacteroides fragilis GroupAntimicrobial Agents and Chemotherapy, 2004
- The GlycylcyclinesDrugs, 2004
- Newer Treatment Options for Skin and Soft Tissue InfectionsDrugs, 2004
- Susceptibilities of Mycoplasma hominis, M. pneumoniae , and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and QuinolonesAntimicrobial Agents and Chemotherapy, 2001
- Mutations in the Interdomain Loop Region of thetetA(A) Tetracycline Resistance Gene Increase Efflux of Minocycline and GlycylcyclinesMicrobial Drug Resistance, 2000